Reirradiation: Standards, challenges, and patient‐focused strategies across tumor types
Abstract
Abstract Reirradiation (reRT), defined as administering a course of radiation therapy to a specific area previously irradiated, is an evolving treatment strategy for locoregionally recurrent cancer that offers significant potential and poses inherent challenges. Advances in such techniques as intensity‐modulated and stereotactic body radiation therapy have improved precision, making reRT a viable option for complex scenarios previously deemed high‐risk. Nevertheless, reRT remains associated with substantial risks—including life‐threatening side effects, functional impairments, and psychosocial effects—which must be carefully balanced against the patient's overall health and the likelihood of achieving cancer control or palliation. Patient selection is essential to optimize outcomes while mitigating risks. Decisions should account for tumor characteristics at the time of primary diagnosis and recurrence, elapsed time since prior treatment, the possibility of delivering meaningful doses to the tumor, and the cumulative irradiation tolerance of normal tissues. Advanced imaging modalities, such as functional magnetic resonance imaging and fluorine‐18–labeled fluorodeoxyglucose–positron emission tomography, are important for distinguishing recurrences from treatment‐induced changes, refining treatment targets, and minimizing exposure to healthy tissue. Combined treatment with systemic regimens—targeted therapies and immunotherapy in particular—offers promising opportunities but requires coordination to manage side effects. Standardized guidelines, such as those from the European Society of Therapeutic Radiology and Oncology‐European Society for Research and Treatment of Cancer, are essential for improving the consistency of reporting, guiding clinical decision making, and fostering patient‐centered care. Multidisciplinary collaboration and ongoing research, particularly through clinical trials, are central to fully exploiting reRT strategies. In addition, the development of innovative techniques, such as proton therapy, would likely enable safer treatments. These efforts aim to improve the therapeutic balance of reRT, enhancing outcomes and quality of life.
Article Details
Authors (22)
Arnaud Beddok
Department of Radiation Oncology Institut Godinot Reims France
Jonas Willmann
Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland
Anna Embring
Department of Oncology Karolinska University Hospital Stockholm Sweden
Ane L. Appelt
Leeds Institute of Medical Research University of Leeds Leeds UK
Panagiotis Balermpas
Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland
Kevin Chua
Division of Radiation Oncology National Cancer Centre Singapore Singapore Singapore
J. Isabelle Choi
Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York USA
Bernice Simone Elger
Institute for Biomedical Ethics, University of Basel Basel Switzerland
Dorota Gabrys
Department of Radiation Oncology Maria Sklodowska‐Curie National Research Institute of Oncology‐Gliwice Branch Glliwice Poland
Peter Hoskin
Mount Vernon Cancer Center and University of Manchester Manchester UK
Maximilian Niyazi
Department of Radiation Oncology University Hospital Tubingen Tubingen Germany
David Pasquier
Academic Department of Radiation Oncology Oscar Lambret Center Lille France
Kelly Paradis
Department of Radiation Oncology Michigan Medicine Ann Arbor Michigan USA
Orit Kaidar‐Person
Oncology Institute Sheba Medical Center Ramat Gan Israel
Corien Plaisier
Reintegration Coach Breda Netherlands
Nicole C. Schmitt
Department of Otolaryngology‐Head and Neck Surgery Emory University School of Medicine Atlanta Georgia USA
Conor E. Steuer
Department of Hematology and Medical Oncology Emory University Atlanta Georgia USA
Juliette Thariat
Department of Radiation Oncology Baclesse Cancer Center Caen France
Sue S. Yom
Department of Radiation Oncology University of California‐San Francisco San Francisco California USA
Philip Poortmans
Department of Radiation Oncology Iridium Netwerk Wilrijk‐Antwerp Belgium
Eliana Vasquez Osorio
Division of Cancer Sciences University of Manchester Manchester UK
Nicolaus Andratschke
Department of Radiation Oncology University Hospital Zurich University of Zurich Zurich Switzerland